Advanced search
Publication Cover
Journal of Pain & Palliative Care Pharmacotherapy Volume 32, 2018 - Issue 2-3
Submit an article Journal homepage
122
Views
3
CrossRef citations to date
0
Altmetric
Article

The Association of Joint Pain and Dipeptidyl Peptidase-4 Inhibitor Use Among U.S. Adults With Type-2 Diabetes Mellitus

Pragya RaiCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-7428-7273
ORCID Icon,
Xiaohui Zhao
&
Usha Sambamoorthi
ORCID Icon
Pages 90-97 | Received 11 Dec 2017, Accepted 02 Nov 2018, Published online: 24 Jan 2019

References

  • WHO. Global status report on noncommunicable diseases 2014. Geneva: World Health Organization; 2014.
  • CDC. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014. Atlanta (GA): U.S. Department of Health and Human Services; 2014.
  • ADA. Standards of medical care in diabetes – 2016. J Clin App Res Edu. 2016;39(S1):1–112.
  • Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care. 2009;32(S32):S151–S156. doi: 10.2337/dc09-S301.
  • Kim SC, Glynn RJ, Liu J, Everett BM, Goldfine AB. Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study. Acta Diabetol. 2014;51(6):1015–1023.
  • Tran L, Zielinski A, Roach AH, et al. Pharmacologic treatment of type 2 diabetes: oral medications. Ann Pharmacother. 2015;49(5):540–556. doi: 10.1177/1060028014558289.
  • Lipska KJ, Yao X, Herrin J, et al. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care 2016;40(4):468–475.
  • Crickx E, Marroun I, Veyrie C, et al. DPP4 inhibitor-induced polyarthritis: a report of three cases. Rheumatol Int. 2014;34(2):291–292. doi: 10.1007/s00296-013-2710-7.
  • Yokota K, Igaki N. Sitagliptin (DPP-4 Inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: a case report. Intern Med. 2012;51(15):2041–2044. doi: 10.2169/internalmedicine.51.7592.
  • Sasaki T, Hiki Y, Nagumo S, et al. Acute onset of rheumatoid arthritis associated with administration of a dipeptidyl peptidase-4 (DPP-4) inhibitor to patients with diabetes mellitus. Diabetol Int. 2010;1(2):90–92. doi: 10.1007/s13340-010-0010-y.
  • Chaicha-Brom T, Yasmeen T. DPP-IV inhibitor-associated arthralgias. Endocr Pract. 2013;19(2):377
  • Tarapués M, Cereza G, Figueras A. Association of musculoskeletal complaints and gliptin use: review of spontaneous reports. Pharmacoepidemiol Drug Saf. 2013;22:1115–1118.
  • FDA. (2015, August 28). Drug Safety and Availability. Retrieved from United States Food and Drug Administration: http://www.fda.gov/Drugs/DrugSafety/ucm459579.htm
  • Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients with Type 2 Diabetes. Diabetes Care. 2006;29(12):2632–2637. doi: 10.2337/dc06-0703.
  • García-Pérez LE, Alvarez M, Dilla T, Gil-Guillén V, Orozco-Beltrán D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4(2):175–194. doi: 10.1007/s13300-013-0034-y.
  • Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav. 1995;36(1):1–10. doi: 10.2307/2137284.
  • Mascolo A, Rafaniello C, Sportiello L, et al. Dipeptidyl Peptidase (DPP)-4 inhibitor-induced arthritis/arthralgia: a review of clinical cases. Drug Saf. 2016;39(5):401–407. doi: 10.1007/s40264-016-0399-8.
  • Huh S, Rice T, Ettner SL. Prescription drug coverage and effects on drug expenditures among elderly medicare beneficiaries. Health Serv Res. 2007;43(3):810–832. doi: 10.1111/j.1475-6773.2007.00804.x.
  • Mahendraratnam N, Dusetzina SB, Farley JF. Prescription drug utilization and reimbursement increased following state medicaid expansion in 2014. J Manag Care Spec Pharm. 2017;23(3):355–363. doi: 10.18553/jmcp.2017.23.3.355.
  • Park YJ, Martin EG. Medicare part D’s effects on drug utilization and out-of-pocket costs: a systematic review. Health Serv Res. 2017;52(5):1685–1728.
  • American diabetes association. Economic costs of diabetes in the US in 2012. Diabetes Care. 2013;36(4):1033–1046.
  • Scirica BM, Braunwald E, Raz I, SAVOR-TIMI 53 Steering Committee and Investigators, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579–1588. doi: 10.1161/CIRCULATIONAHA.114.010389.
  • Green JB, Bethel MA, Armstrong PW, TECOS Study Group, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242. doi: 10.1056/NEJMoa1501352.
  • Eurich D, Simpson S, Senthilselvan A, Asche C, Sandhu-Minhas J, McAlister F. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. BMJ. 2013;346:f2267.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.